Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. International Most cancers Observatory: Most cancers At the moment. [(accessed on 1 Feb 2023)]. Accessible on-line: https://gco.iarc.fr/at this time
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. International Most cancers Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Nations. CA Most cancers J Clin. 2021;71:209–49.
Spechler SJ, Souza RF. Barrett’s esophagus. N. Engl J Med. 2014;371:836–45.
Quante M, Graham TA, Jansen M. Insights Into the Pathophysiology of Esophageal Adenocarcinoma. Gastroenterology. 2018;154:406–20.
Doorakkers E, Lagergren J, Santoni G, Engstrand L, Brusselaers N. Helicobacter pylori eradication therapy and the danger of Barrett’s esophagus and esophageal adenocarcinoma. Helicobacter. 2020;25:e12688.
Coleman HG, Xie SH, Lagergren J. The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology. 2018;154:390–405.
Reynolds JV, Preston SR, O’Neill B, Lowery MA, Baeksgaard L, Crosby T, et al. Trimodality remedy versus perioperative chemotherapy within the administration of regionally superior adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, section 3 trial. Lancet Gastroenterol Hepatol. 2023;8:1015–27.
Imamura Y, Watanabe M, Oki E, Morita M, Baba H. Esophagogastric junction adenocarcinoma shares traits with gastric adenocarcinoma: Literature overview and retrospective multicenter cohort research. Ann Gastroenterol Surg. 2021;5:46–59.
Kato Okay, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, et al. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in superior esophageal squamous cell carcinoma: a Japanese subgroup evaluation of open-label, section 3 trial (CheckMate 648/ONO-4538-50). Esophagus. 2023;20:291–301.
Janjigian YY, Shitara Okay, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for superior gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, section 3 trial. Lancet. 2021;398:27–40.
Integrative HMP (iHMP) Analysis Community Consortium. The Integrative Human Microbiome Venture. Nature. 2019;569:641–8.
Galeano Nino JL, Wu H, LaCourse KD, Kempchinsky AG, Baryiames A, Barber B, et al. Impact of the intratumoral microbiota on spatial and mobile heterogeneity in most cancers. Nature. 2022;611:810–7.
Fan Y, Pedersen O. Intestine microbiota in human metabolic well being and illness. Nat Rev Microbiol. 2021;19:55–71.
Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human most cancers. Science. 2021;371:eabc4552.
Holt RA, Cochrane Okay. Tumor Potentiating Mechanisms of Fusobacterium nucleatum, A Multifaceted Microbe. Gastroenterology. 2017;152:694–6.
Brennan CA, Garrett WS. Fusobacterium nucleatum – symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17:156–66.
Ugai T, Shimizu T, Kawamura H, Ugai S, Takashima Y, Usui G, et al. Inverse relationship between Fusobacterium nucleatum quantity and tumor CD274 (PD-L1) expression in colorectal carcinoma. Clin Transl Immunol. 2023;12:e1453.
Mima Okay, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura Okay, et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol. 2015;1:653–61.
Mima Okay, Cao Y, Chan AT, Qian ZR, Nowak JA, Masugi Y, et al. Fusobacterium nucleatum in Colorectal Carcinoma Tissue In response to Tumor Location. Clin Transl Gastroenterol. 2016;7:e200.
Mima Okay, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and affected person prognosis. Intestine. 2016;65:1973–80.
Wang N, Fang JY. Fusobacterium nucleatum, a key pathogenic issue and microbial biomarker for colorectal most cancers. Developments Microbiol. 2023;31:159–72.
Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, et al. Fusobacterium nucleatum Will increase Proliferation of Colorectal Most cancers Cells and Tumor Growth in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Issue-kappaB, and Up-regulating Expression of MicroRNA-21. Gastroenterology. 2017;152:851–66.e824.
Zhang Y, Zhang L, Zheng S, Li M, Xu C, Jia D, et al. Fusobacterium nucleatum promotes colorectal most cancers cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-kappaB/ICAM1 axis. Intestine Microbes. 2022;14:2038852.
Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum an infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306.
Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic evaluation identifies affiliation of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–8.
Lee DW, Han SW, Kang JK, Bae JM, Kim HP, Gained JK, et al. Affiliation Between Fusobacterium nucleatum, Pathway Mutation, and Affected person Prognosis in Colorectal Most cancers. Ann Surg Oncol. 2018;25:3389–95.
Lee JB, Kim KA, Cho HY, Kim D, Kim WK, Yong D, et al. Affiliation between Fusobacterium nucleatum and affected person prognosis in metastatic colon most cancers. Sci Rep. 2021;11:20263.
Yamamura Okay, Baba Y, Nakagawa S, Mima Okay, Miyake Okay, Nakamura Okay, et al. Human Microbiome Fusobacterium Nucleatum in Esophageal Most cancers Tissue Is Related to Prognosis. Clin Most cancers Res. 2016;22:5574–81.
Yamamura Okay, Baba Y, Miyake Okay, Nakamura Okay, Shigaki H, Mima Okay, et al. Fusobacterium nucleatum in gastroenterological most cancers: Analysis of measurement strategies utilizing quantitative polymerase chain response and a literature overview. Oncol Lett. 2017;14:6373–8.
Nomoto D, Baba Y, Liu Y, Tsutsuki H, Okadome Okay, Harada Okay, et al. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma development through the NOD1/RIPK2/NF-kappaB pathway. Most cancers Lett. 2022;530:59–67.
Di Pilato V, Freschi G, Ringressi MN, Pallecchi L, Rossolini GM, Bechi P. The esophageal microbiota in well being and illness. Ann N. Y Acad Sci. 2016;1381:21–33.
Guo Y, Cao XS, Zhou MG, Yu B. Gastric microbiota in gastric most cancers: Completely different roles of Helicobacter pylori and different microbes. Entrance Cell Infect Microbiol. 2022;12:1105811.
Guccione C, Yadlapati R, Shah S, Knight R, Curtius Okay. Challenges in Figuring out the Position of Microbiome Evolution in Barrett’s Esophagus and Development to Esophageal Adenocarcinoma. Microorganisms. 2021;9:2003.
Brusilovsky M, Bao R, Rochman M, Kemter AM, Nagler CR, Rothenberg ME. Host-Microbiota Interactions within the Esophagus Throughout Homeostasis and Allergic Irritation. Gastroenterology. 2022;162:521–34.e528.
Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Irritation and intestinal metaplasia of the distal esophagus are related to alterations within the microbiome. Gastroenterology. 2009;137:588–97.
Muszynski D, Kudra A, Sobocki BK, Folwarski M, Vitale E, Filetti V, et al. Esophageal most cancers and bacterial a part of intestine microbiota – A multidisciplinary perspective. Entrance Cell Infect Microbiol. 2022;12:1057668.
Shao D, Vogtmann E, Liu A, Qin J, Chen W, Abnet CC, et al. Microbial characterization of esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-risk area of China. Most cancers. 2019;125:3993–4002.
Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, et al. Lengthy-term adjustments of intestine microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19:1109–20.
Freedberg DE, Kim LS, Yang YX. The Dangers and Advantages of Lengthy-term Use of Proton Pump Inhibitors: Knowledgeable Overview and Finest Follow Recommendation From the American Gastroenterological Affiliation. Gastroenterology. 2017;152:706–15.
Amieva M, Peek RM Jr. Pathobiology of Helicobacter pylori-Induced Gastric Most cancers. Gastroenterology. 2016;150:64–78.
Schulz C, Schutte Okay, Koch N, Vilchez-Vargas R, Wos-Oxley ML, Oxley APA, et al. The energetic bacterial assemblages of the higher GI tract in people with and with out Helicobacter an infection. Intestine. 2018;67:216–25.
Boehm ET, Thon C, Kupcinskas J, Steponaitiene R, Skieceviciene J, Canbay A, et al. Fusobacterium nucleatum is related to worse prognosis in Lauren’s diffuse sort gastric most cancers sufferers. Sci Rep. 2020;10:16240.
Lagergren J, Lagergren P. Current developments in esophageal adenocarcinoma. CA Most cancers J Clin. 2013;63:232–48.
Cossentino MJ, Wong RK. Barrett’s esophagus and threat of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14:128–35.
Pohl H, Wrobel Okay, Bojarski C, Voderholzer W, Sonnenberg A, Rosch T, et al. Danger elements within the growth of esophageal adenocarcinoma. Am J Gastroenterol. 2013;108:200–7.
Gao P, Cai N, Yang X, Yuan Z, Zhang T, Lu M, et al. Affiliation of Helicobacter pylori and gastric atrophy with adenocarcinoma of the esophagogastric junction in Taixing, China. Int J Most cancers. 2022;150:243–52.
Johnson DA, Fennerty MB. Heartburn severity underestimates erosive esophagitis severity in aged sufferers with gastroesophageal reflux illness. Gastroenterology. 2004;126:660–4.
Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling through its FadA adhesin. Cell Host Microbe. 2013;14:195–206.
Wu B, Crampton SP, Hughes CC. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity. 2007;26:227–39.
Shi S, Liu Y, Wang Z, Jin X, Yan W, Guo X, et al. Fusobacterium nucleatum induces colon anastomosis leak by activating epithelial cells to specific MMP9. Entrance Microbiol. 2022;13:1031882.
